¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (3ÀÏÂ÷) : 2022-05-28

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (3ÀÏÂ÷) : 2022-05-28
±³À°ÀÏÀÚ : 2022-05-28
±³À°Àå¼Ò : ¼­¿ï µå·¡°ï½ÃƼȣÅÚ  
±³À°ÁÖÁ¦ : KSN(Korea Society of Nephrology) 2022 (3ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°úÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 31 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í ¡áȸ¿ø: »çÀü(100,000)/ÇöÀå(150,000) ¡áºñȸ¿ø: »çÀü(150,000)/ ÇöÀå(200,000) ¡áFellow-in-training,Resident,Trainee,Student,Nurse,etc: »çÀü(50,000)/ ÇöÀå(35,000) *Medical Student: ¸éÁ¦      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-28 Room 1(5F) 08:30~09:00 Uptodate Review of the Management of Diabetes in Hemodialysis Patients  °íÀº½Ç(¿©Àǵµ¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 09:00~09:30 Uptodate Review of Intradialytic Hypotension - Mechanism, Clinical Impacts and Management  ¹Ú¿ì¿µ(°è¸íÀÇ´ë ½ÅÀå³»°ú) 
±³À°½Ã°£ 05-28 Room 1(5F) 09:30~10:00 Uptodate Review of Restless Legs Syndrome - Mechanism, Clinical Impacts and Management  ±æÈ¿¿í(õ¾È¼øõÇ⺴¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 10:00~10:30 Uptodate Review of Antithrombotic Therapy for Hemodialysis Patients With Atrial Fibrillation  ¼Û¿µ¸²(ÇѸ²´ëÇб³¼º½Éº´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 10:40~11:10 Impact of Sarcopenia on Mortality in Patients Undergoing Hemodialysis  ÁöÁ¾Çö(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 11:10~11:40 National Quality Control of Hemodialysis in Korea; A Small Carrot and a Big Stick  ±Ç¼ø±æ(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 1(5F) 11:40~12:10 Effect of Dialysis Modality on Chronic Inflammation and Oxidative Stress in Maintenance Hemodialysis Patients  Minoru Satoh(Japan Organization of Occupational Health and Safety Kobe Rosai Hospital) 
±³À°½Ã°£ 05-28 Room 1(5F) 12:10~12:40 Japanese Reimbursement System for Hemodialysis and Online Hemodiafiltration  Yoshihiro Ota(Nagoya Memorial Hospital) 
±³À°½Ã°£ 05-28 Room 1(5F) 15:00~15:30 How to Assess Volume Status in Critically Ill Patients  ÀÓ¼ºÀ±(ºÐ´ç¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 15:30~16:00 Fluid Versus Vasopressor Therapy in Resuscitation  ¿©ÇýÁÖ(¾ç»êºÎ»ê´ëº´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 16:00~16:30 Electrolyte Disturbances in the Neuro Intensive Care Unit  ÀÌÁ¤È¯(¼­¿ïƯº°½Ãº¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 16:30~17:00 Approaches to Acid-base Disorders: Traditional Versus Stewart  Á¤¼ºÁø(¿©Àǵµ°¡Å縯¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 17:10~17:40 What Is Aging?; Is Aging a Natural Condition or a Disease?  Hidenori Arai(National Center for Geriatrics and Gerontology) 
±³À°½Ã°£ 05-28 Room 1(5F) 17:40~18:10 Aging and Kidney Disease  ±è¼­¸°(¾ç»êºÎ»ê´ëº´¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 18:10~18:40 Aging Interventions and Therapies  ±ÇÀº¼ö(Çѱ¹»ý¸í°øÇבּ¸¿ø) 
±³À°½Ã°£ 05-28 Room 1(5F) 18:40~19:10 Medical Service for Healthy Aging  Reshma A. Merchant(National University Hospital) 
±³À°½Ã°£ 05-28 Room 2(3F) 08:30~09:00 Kidney Disease Improving Global Outcomes Recommendations for Home Dialysis  Martin Wilkie(Sheffield Kidney Institute) 
±³À°½Ã°£ 05-28 Room 2(3F) 09:00~09:30 Peritoneal Dialysis Outcomes and Practice Patterns Study Korea and Global  ¿À±¹È¯(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-28 Room 2(3F) 09:30~10:00 Incremental Peritoneal Dialysis  ¾È¿ø¼®(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 2(3F) 10:00~10:30 Malnutrition in Peritoneal Dialysis  °­¼®ÈÖ(¿µ³²´ëÇб³ÀÇ·á¿ø) 
±³À°½Ã°£ 05-28 Room 2(3F) 10:40~11:10 Overview of Thrombotic Microangiopathy Including COVID-19  ±èÁø¼®(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-28 Room 2(3F) 11:10~11:40 Cytopathology in Shigatoxigenic and verotoxigenic Escherichia coli/enterohemorrhagic E. coli-Hemolytic–uremic syndrome  Á¶¸íÇö(ÇѸ²´ëÇб³¼º½Éº´¿ø) 
±³À°½Ã°£ 05-28 Room 2(3F) 11:40~12:10 Complementopathy in Atypical Hemolytic–uremic syndrome/C3 Glomerulopathy  ±è¸í±Ô(°í·Á´ëÇб³¾È¾Ïº´¿ø) 
±³À°½Ã°£ 05-28 Room 2(3F) 12:10~12:40 Clinical Use of Eculizumab and Ravulizumab  Fadi Fakhouri(Nantes University Hospital Center) 
±³À°½Ã°£ 05-28 Room 2(3F) 15:00~15:30 Optimizing the Corticosteroid Dose in Steroid-sensitive Nephrotic Syndrome  Martin Christian(Nottingham University Hospital) 
±³À°½Ã°£ 05-28 Room 2(3F) 15:30~16:00 Nephrotic Syndrome Requiring Other than Steroid; Coenzyme Q10 Nephropathy  ¹ÚÀ¯Áø(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 2(3F) 16:00~16:30 What We Learned from Nephrotic Syndrome Registry Studies and Its Implication for Treatment  Susan Samuel(University of Calgary) 
±³À°½Ã°£ 05-28 Room 2(3F) 16:30~17:00 Childhood-nephrotic Syndrome in Adult Patients  ¼­Áø¼ø(ºÎõ°¡Å縯¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-28 Room 2(3F) 17:10~17:40 The Key Advances in the Pathogenesis of Immunoglobulin A Nephropathy  Jonathan Barratt(University of Leicester) 
±³À°½Ã°£ 05-28 Room 2(3F) 17:40~18:10 The Key Updates in the 2021 Kidney Disease Improvement Global Outcome Guideline for Immunoglobulin A Nephropathy and New Therapies in for IgA Nephropathy  Hong Zhang(Peking University First Hospital) 
±³À°½Ã°£ 05-28 Room 2(3F) 18:10~18:40 Beyond Mycophenolate and Cyclophosphamide for Lupus Nephritis  ¼­Ã¢Èñ(¾ÆÁÖ´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-28 Room 2(3F) 18:40~19:10 New Pathophysiology and Clinical Approach in Tubulointerstitial Nephritis  Çѽ¼®(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-28 Room 2+3+4(3F) 14:00~14:50 Oxygen Biology in the Kidney  Masaomi Nangaku(The University of Tokyo Graduate School of Medicine) 
±³À°½Ã°£ 05-28 Room 3(3F) 08:30~09:00 High Protein Diet-Induced Glomerular Hyperfiltration  °í°­Áö(°í·ÁÀǴ뱸·Îº´¿ø) 
±³À°½Ã°£ 05-28 Room 3(3F) 09:00~09:30 Clinical Dilemmas in Heart Failure and Chronic Kidney Disease Management  Sunita Bavanandan(Hospital Kuala Lumpur) 
±³À°½Ã°£ 05-28 Room 3(3F) 09:30~10:00 Transform, Optimization of Animal Studies to Develop New Drugs  Masaomi Nangaku(The University of Tokyo Graduate School of Medicine) 
±³À°½Ã°£ 05-28 Room 3(3F) 10:00~10:30 Single Cell Research Update in Kidney Disease  ¹ÚÁöȯ(±¤ÁÖ°úÇбâ¼ú¿ø) 
±³À°½Ã°£ 05-28 Room 3(3F) 10:40~11:10 A Long Journey for Acute Kidney Injury Biomarkers  ½ÅÁ¤È£(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 3(3F) 11:10~11:40 Using Computer Science to Assist Acute Kidney Injury Care - From E-alert to Artificial Intelligence  Chih-Hsiang Chang(Chang Gung Memorial Hospital) 
±³À°½Ã°£ 05-28 Room 3(3F) 11:40~12:10 Prevention and Treatment of Acute Kidney Injury From the Viewpoint of Renal Congestion  Masanori Abe(Nihon University) 
±³À°½Ã°£ 05-28 Room 3(3F) 12:10~12:40 Therapeutic Exosomes for Acute Kidney Injury  ±è¼ºÈÆ(¿¬¼¼´ëÇб³ Ä¡ÀÇ°ú´ë) 
±³À°½Ã°£ 05-28 Room 3(3F) 15:00~15:30 Clinical Consideration in Using Sodium-Glucose Linked Transporter-2 Inhibitors  Meg Jardine(University of Sydney) 
±³À°½Ã°£ 05-28 Room 3(3F) 15:30~16:00 Clinical Consideration in Using MRAs  ±è¿¹¸²(°è¸íÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 3(3F) 16:00~16:30 Pleotropic Effects of HIF-PHIs, Are There Clinical Relevant  Yu-Hsiang Chou (National Taiwan University) 
±³À°½Ã°£ 05-28 Room 3(3F) 16:30~17:00 Renoprotective Effect of ET Inhibitor  ¿À¼¼¿ø(°í·Á´ëÇб³¾È¾Ïº´¿ø) 
±³À°½Ã°£ 05-28 Room 3(3F) 17:10~17:40 Advances in Immunoglobulin A Nephropathy  ¿ÀÅ·Å(Àü³²´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-28 Room 3(3F) 17:40~18:10 Advances in Membranous Nephropathy  Vivek Jha(The George Institute for Global Health) 
±³À°½Ã°£ 05-28 Room 3(3F) 18:10~18:40 Advances in atypical Hemolytic Uremic Syndrome /Thrombotic Microangiopathy  °­ÀºÁ¤(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 3(3F) 18:40~19:10 Advances in Lupus Nephritis  Kah Mean Thong(Hospital Ipoh) 
±³À°½Ã°£ 05-28 Room 4(3F) 08:30~08:40 Gut Microbial Genes and Metabolism for Methionine and Branched-Chain Amino Acids in Diabetic Nephropathy  ±èÁöÀº(°í·ÁÀǴ뱸·Îº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 08:40~08:50 Non-invasive Biomarker Using Urinary Exosome miRNA That Reflects Pathologic Features of Patients With Diabetic Kidney Diseases  ±è´ë±Ô(°­µ¿°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 08:50~09:00 Curcumin Blocks High Glucose-Induced Podocyte Injury via Receptor-interacting serine/threonine-protein kinase 3 -Dependent Pathway  À̼º¿ì(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 4(3F) 09:00~09:10 Periostin Deficiency Attenuates Kidney Fibrosis and Pancreatic ¥â-Cell Dysfunction Though Reducing Tenascin C Under Diabetic Conditions  Á¶¾Æ¶ó(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-28 Room 4(3F) 09:10~09:20 Effects of Zinc Oxide Nanoparticles on Oxidative Stress and Renal Function in Fat-Fed and Streptozotocin-Treated Rats  Pardeep Kumar(F H M College and Hospital) 
±³À°½Ã°£ 05-28 Room 4(3F) 09:20~09:30 Similar Risk of Kidney Function Decline Between Tenofovir Alafenamide and Besifovir Dipivoxil Maleate in Chronic Hepatitis B  Á¤Âù¿µ(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 09:30~09:40 Urinary Sodium-To-Potassium Ratio and Chronic Kidney Disease Progression in Non-dialysis-Dependent Chronic Kidney Disease Patients: Results From the KNOW-Chronic Kidney Disease Study  °­µ¿Çõ(°í·ÁÀǴ뱸·Îº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 09:40~09:50 Long-Term Exposure to High Perceived Temperature and Risk for Mortality Among Chronic Kidney Disease Patients  ÀÌÁ¤È¯(¼­¿ïƯº°½Ãº¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 09:50~10:00 SGLT2 Inhibitor Reduces Urinary Mitochondrial DNA in Chronic Kidney Disease Patients With or Without Type 2 Diabetes Mellitus  ÀÌÇØ°æ(¼øõÇâ´ëÇб³º´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 10:00~10:10 Age-Specific Estimated Glomerular Filtration Rate and Outcomes: Insights From the KNOW-Chronic Kidney Disease Cohort  ±èÁöÇý(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 10:10~10:20 Development and Validation of Deep Learning Algorithm for Evaluating Kidney Function Based on Electrocardiogram  ¾ÈÁ¤³²(ÇѸ²´ëÇб³¼º½Éº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 10:20~10:30 Rosuvastatin Inhibits Tubulointerstitial Fibrosis via Activating HOX13-BMP-7 Pathway  ¿Àµ¿È¯(°­³²¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 10:40~11:10 Artificial intelligence Application in Renal Pathology  °íÇöÁ¤(¿ï»êÀÇ´ë ¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 11:10~11:40 Expert-Level Segmentation Using Deep Learning for Volumetry of Autosomal Dominant Polycystic Kidney Disease  ¹è°æÅÂ(University of Pittsburgh) 
±³À°½Ã°£ 05-28 Room 4(3F) 11:40~12:10 Building Risk Prediction Models in Acute Kidney Injury  ¹ÎÁö¿ø(ºÎõ°¡Å縯¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 12:10~12:40 AI Application to Improve Hemodialysis Adequacy  ±èÇü¿ì(¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 15:00~15:30 The Evolution of Evidence Generation in Chronic Kidney Disease-Anemia: A History of Agents and Trial Designs  Wolfgang Winkelmayer(Baylor College of Medicine) 
±³À°½Ã°£ 05-28 Room 4(3F) 15:30~16:00 Anemia in Chronic Kidney Disease Patients: Result From the Know-Chronic Kidney Disease  ¿À±¹È¯(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 16:00~16:30 HIF-PHI Trials in Chronic Kidney Disease Non-dialysis and Dialysis: What Do the Data Really Show?  David Wheeler(University College London) 
±³À°½Ã°£ 05-28 Room 4(3F) 16:30~17:00 Appropriate use of Hypoxia-Inducible Factor Prolyl Hydroxylase inhibitor in Korean with Chronic Kidney Disease  ±è¼º±Õ(ÇѸ²´ëÇб³¼º½Éº´¿ø) 
±³À°½Ã°£ 05-28 Room 4(3F) 17:00~17:30 The Evolving Roles of Iron Treatment, ESAs, and Hypoxia-inducible factor prolyl hydroxylase Inhibitors Towards Successful Anemia Treatment  Elain Ku(University of California , San Francisco) 
±³À°½Ã°£ 05-28 Room 4(3F) 17:30~18:00 Treatment of Anemia:Beyond Erythropoietin in Korea 2022  ÁöÁ¾Çö(°­³²¼¼ºê¶õ½ºº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ KSN(Korea Society of Nephrology) 2022 (3ÀÏÂ÷) : 2022-05-28""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦17Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ : 2022-05-29
´ÙÀ½±Û (¿Â¶óÀÎ) ¿µµîÆ÷±¸ÀÇ»çȸ 2022³â ¿Â¶óÀÎ Çмú´ëȸ : 2022-05-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21088 ºÎ»ê 2024 ´ëÇѺñ¸¸ÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°­Á : 2024-07-06 0 5 2024-06-18
21087 ¼­¿ï 2024 °­ºÏ»ï¼ºº´¿ø ¼ÒÈ­±â ½ÉÆ÷Áö¾ö : 2024-07-06 0 5 2024-06-18
21086 ´ëÀü Çѱ¹È£½ºÇǽº¡¤¿ÏÈ­ÀÇ·áÇÐȸ 2024³â ÇÏ°èÇмú´ëȸ : 2024-07-06 0 6 2024-06-18
21085 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2024 Á¶¿µÁ¦ ¾ÈÀü°ü¸® ½ÉÆ÷Áö¾ö : 2024-07-06 0 2 2024-06-18
21084 ¼­¿ï Á¦22ȸ ¼­¿ï½Ã ³²¼­ 7°³±¸ ÀÇ»çȸ ÇÕµ¿ Çмú´ëȸ : 2024-07-06 0 0 2024-06-18
21083 ±¤ÁÖ ±¤ÁÖÀü³²³»°úÀÇ»çȸ Á¦6ȸ ÃÊÀ½ÆÄ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-07-06 0 1 2024-06-18
21082 ¼­¿ï 2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 1 2024-06-18
21081 °­¿ø 2024³â ´ëÇѳ»°úÇÐȸ °­¿øÁöȸ ÇÏ°è ¿¬¼ö°­Á : 2024-07-06 0 0 2024-06-18
21080 °æ±â 2024³â °í´ë¾È»ê ³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 0 2024-06-18
21079 ¼­¿ï 2024 È£Èí±â°¨¿°º´ ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 1 2024-06-18
21078 ºÎ»ê ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ&ÁöºÎ ½ÉÆ÷Áö¾ö-ºÎ¿ï°æ : 2024-07-06 0 1 2024-06-18
21077 ¼­¿ï ´ëÇÑÅ»ÀåÇÐȸ 18th Congress of the KHS & 2024 International Symposium(2ÀÏÂ÷) : 2024-07-06 0 1 2024-06-18
21076 ¼­¿ï ´ëÇÑ¿Ü°úÃÊÀ½ÆÄÇÐȸ 2024 Breast Biopsy Symposium : 2024-07-06 0 1 2024-06-18
21075 ¼­¿ï 2024³â ´ëÇѼö¸é¿¬±¸ÇÐȸ Á¤±â Çмú´ëȸ DAY 1 : 2024-07-06 0 1 2024-06-18
21074 ±¤ÁÖ 2024³âµµ ´ëÇÑÇǺΰúÀÇ»çȸ ±¤ÀüÁöºÎ ±³À°½ÉÆ÷Áö¿ò : 2024-07-06 0 1 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷